# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055053
Filing Date
2024-05-08
Accepted
2024-05-08 07:04:28
Documents
56
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | sndx-20240331.htm iXBRL | 10-Q | 1488756
2 | EX-31.1 | sndx-ex31_1.htm | EX-31.1 | 13328
3 | EX-31.2 | sndx-ex31_2.htm | EX-31.2 | 13858
4 | EX-32.1 | sndx-ex32_1.htm | EX-32.1 | 12042
| Complete submission text file | 0000950170-24-055053.txt |  | 6388749

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | sndx-20240331.xsd | EX-101.SCH | 1035933
59 | EXTRACTED XBRL INSTANCE DOCUMENT | sndx-20240331_htm.xml | XML | 1061619

Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37708 | Film No.: 24924199
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)